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Drug testing using soft agar clonogenic techniques
has been the focus of much attention in the last ten
years. The overall aim of such tests has been to
predict and therefore select the most effective
chemotherapy for the individual patient. Since the
reports by Hamburger & Salmon (1977),
Hamburger et al. (1978) and Salmon et al. (1978)
many centres have been involved in using this
technique with varying degrees of success and
several reviews on the subject have been published
(Weisenthal, 1981; Mattern & Volm, 1982; Hill,
1983). There are, however, many unresolved
practical problems pertaining to direct testing of
patient tumour samples. The low number of
tumour samples which clone in agar and the
absolute requirement for a single cell suspension
have been frequently cited (Agrez et al., 1982;
Bertoncello et al., 1982; Hanson et al., 1984).
Cytotoxicity tests based on labelled precursor
uptake lose the specificity for evaluating only the
clonogenic cell population as all proliferating cells
will contribute to the observed uptake. However,
the evaluation of this population of cells, which
include the truly clonogenic cells, may well be more
realistic for patients with late stage disease where
the clonogenic fraction only accounts for a small
percentage of the total cell proliferative population
(Wilson, 1984). Such assays do offer the advantage
over clonogenic assays of not requiring a pure
single cell suspension. They also remove the
subjective element in scoring colonies and results
can be obtained usually within a week which is a
substantial improvement on the 3 to 6 weeks
required for clonogenic assays of primary human
tumour cells.
Attempts have been made to combine short term
growth in soft agar with incorporation and
subsequent measurement of labelled nucleoside.
Such an approach retains the specificity of agar for
the growth of tumour cells and the inhibition of
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most normal cells yet allows for great savings in
terms of time. Tanigawa et al. (1982), using both
cell lines and cells prepared directly from human
tumours, reported good correlations between the
measured clonogenic survival and the depression in
uptake of [3H]TdR in drug-treated cells compared
to controls. A liquid top layer system where cells
are cultured over an agar base as developed by
Friedman & Glaubiger (1982) offers the advantage
over the latter technique as cells can be harvested
directly and do not have to be released from the
supporting gel.
To determine the potential application of a short
term labelling assay we have directly compared the
soft agar clonogenic assay, developed by Courtenay
& Mills (1978), with the short term test developed
by Friedman & Glaubiger (1982) based on the
inhibition in uptake of [3H]TdR. We have used
human tumour xenograft cells of low cloning
efficiency in soft agar as opposed to high cloning
established cell lines as these cells approximate
more closely to those obtained from tumour biopsy
samples.
Details of the xenografts studied are summarised
in Table I. Tumour lines were routinely maintained
in thymectomised, irradiated CBA mice (Steel et al.,
1978). Single cell suspensions were prepared from
the xenografts and finally filtered through a 27,um
Table I Human tumour xenograft characteristics
CEl in
HTX code Origin Histology soft agar
V7 Ovary Poorly differentiated 0.03-0.12
carcinoma
V15 Skin Melanoma ND
nodule
V24 Ovary Endometrioid -.0.003
carcinoma
HX99 Breast Adenocarcinoma -0.01
aCloning efficiency; ND =Not determined.
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mesh. Cells were exposed to drugs (1 h) or radiation
(from a caesium source emitting gamma rays of
0.66Mev and at a dose rate of 0.975Gymin-1)
and, following subsequent washes in the case of
drug exposures, the cell suspensions were divided
half being used for the clonogenic assay and half
being used in the [3H]TdR uptake assay. Cultures
set up in both assay systems were incubated in an
atmosphere of 5% oxygen, 5% carbon dioxide and
90% nitrogen. In the clonogenic assay, cells were
seeded to give -400 colonies per control culture.
Colonies of >50 cells were scored after 3 weeks.
The [3H]TdR assay used was similar to that
described by Friedman & Glaubiger (1982) and was
recently described in detail by Twentyman et al.
(1984). Essentially this involved culturing treated
cells in culture medium over agar base coated petri
dishes for 4 days before incubating for a further
24h with [3H]TdR (I pCiml-1; 51 Cimmol-1).
In the dose response experiments, the count rate of
treated samples was expressed as a proportion of
that of untreated controls. The average standard
error within experiments was 12.6% of the mean
for colony counts and 8.6% for liquid scintillation
counts of incorporated [3H]TdR. Each point in
Figures 1 and 2 represents the mean of triplicate
cultures.
Preliminary experiments with V7, an ovarian
human tumour xenograft, demonstrated a linear
relationship between cell seeding density and both
colony number (between 5 to 103 colonies) scored
after 3 weeks and the rate of uptake of [3H]TdR
(between 103 to 105c.p.m.) measured after 4 days in
culture.
0.
C.)
CY)
00 Un ° 0
0
0
0 °
0 1 2
Gray
Figure 1 V7 cell response following radiation
exposure. Pooled data from 4 experiments. (0---0)
Inhibition in rate of [3H]TdR uptake; (*-@)
clonogenic survival. The [3H]TdR uptake data was
divided into two and analysed separately, the two
straight lines being joined by eye.
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Figure 2 V7 cell response following exposure to: (a) melphalan pooled data from 2 experiments; (b) cisplatin
pooled data from 2 experiments; (c) vinblastine. (0 O) Inhibition in rate of [3H]TdR uptake; (0 *)
clonogenic survival.
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Time course experiments demonstrated that the
four xenograft lines tested showed very individual
patterns in the rate of [3H]TdR uptake over the
first week in culture. V15 showed a decreasing rate
of [3H]TdR uptake. HX99 displayed an initial
increase in uptake followed by a plateau phase with
the rate of uptake remaining virtually unchanged
after the second day in culture. Both V24 and V7
showed an increase in the rate of uptake of label
over the first 7 days in culture. Increasing the cell
seeding density did not change the overall pattern
of [3H]TdR uptake. The V7 xenograft line was used
in all subsequent experiments.
Dose response data for the V7 xenograft
following exposure to radiation and melphalan,
cisplatin and vinblastine are shown in Figures 1 and
2. All data, where a direct comparison of the two
assays was possible, are summarised in Figure 3.
The data show good agreement for the agents
tested over the first 1.5 to 2 decades of cell
response. There is however an apparent increase in
resistance as measured by the [3H]TdR uptake
assay once the rate of uptake of [3H]TdR falls to
1% and below that of controls. The plateau in
response (Figures 1 and 2a) is similar to the
findings of Twentyman et al. (1984) who noted the
tendency for the [3H]TdR assay to plateau at
between one to two decades of cell response after
treatment of H69 lung xenograft cells with X-rays
and the cytotoxic drugs adriamycin, melphalan,
nitrogen mustard and CCNU.
In the case of primary tumour cells and slow-
growing cell lines, 4 days in culture may only
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Figure 3 Correlation of all dose response data for the
V7 xenograft line as measured by the soft agar
clonogenic assay and the [3H]TdR uptake assay.
Survival measured as inhibition in rate of [3H]TdR
uptake or colony survival following exposure to (C1)
cisplatin, (@) vinblastine (0) pmelphalan and (A)
radiation. (-) represents the line equivalence. (---)
represents the linear regression r=0.958.
represent 1 or 2 cell divisions and assaying at this
time point may well pre-empt full recovery from the
drug/radiation-perturbed state (Weisenthal, 1981).
In spite of this our initial results with the low
cloning V7 xenograft line indicate that cell response
as determined by the [3H]TdR uptake assay
following short term culture of 4 to 6 days is in
good agreement with clonogenic survival over the
first two decades of cell kill. Increasing the time of
assay in the [3H]TdR uptake experiments from day
4 to days 5 and 6 had little effect on the overall
measured cell response following radiation doses of
1 and 3Gy. The mean inhibition in [3H]TdR
uptake at these doses was 0.26 and 0.026
respectively and the comparative clonogenic
survival was 0.22 and 0.015.
Presumably, both proliferative but non-
clonogenic and truly-clonogenic cells will either
show unperturbed growth, repair of damage
followed by subsequent growth or cell death. The
combination of these factors plus cycle delay may
well give rise to the apparent decreased sensitivity
to higher doses of drugs and radiation. A limitation
ofworking with cells of low cloning efficiency is the
narrow range of cell kill measurable without
increasing the initial number of cells plated. Our
clonogenic survival data is therefore limited below
the 0.01 level and no comments can be made
concerning the clonogenic survival corresponding to
the plateau regions seen in the [3H]TdR uptake
assay (Figures 1 and 2a). Current work involving
both autoradiography and further investigating the
change in response between days 0 and 6 for both
high and low cloning lines may explain firstly
which cell population(s) are responsible for uptake
of label in the first few days of culture and
secondly how long it takes doomed cells to die and
cease incorporation oflabelled thymidine.
We plan to further these studies to investigate
[3H]TdR uptake in our other low cloning xenograft
lines and in primary samples of human tumours.
Provided reasonable levels of label uptake are
obtained in primary tumour cells, the 4 day
labelling uptake assay may be of use for individual
patient chemosensitivity testing. As the [3H]TdR
uptake assay does not require the complete
disaggregation of cell clumps into a single cell
suspension, this assay could well increase the
numbers of samples available for drug testing,
shorten the time required for results and increase
the potential for an effective individualised patient
chemotherapy.
The HX99 xenograft was kindly donated by Dr A.C.
Jones of the Institute of Cancer Research, Sutton. We are
grateful to Mr J. Court for helpful discussions in the
preparation of this manuscript and to Mrs A. Pritchard
for her assistance with the maintainance of the xenograft
tumour lines.
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